BioMimetix is developing a new class of redox active metalloporphyrins for the treatment of cancer patients.
The drugs are uniquely potent in increasing survival by augmenting cancer killing in chemotherapy and radiation therapy.


Increasing survival of patients with glioblastoma 50%.
Early indications for protection of cognition and protection of bone marrow from injury by chemotherapy.
Protection from the severe and disabling side effects of radiation therapy.


Improving Quality of Life by controlling chronic inflammatory skin conditions and their disabling symptoms including itch, pain and appearance.